I said that NICE says they won't work when one has already stopped working.
The evidence from other countries is that's not quite correct. I spoke with an oncologist who practices in the UK and the US, and he said that in about 20% of cases, serial use of Abiraterone and Enzalutamide in the US does continue working for longer. It's also easy to try to see if the patient is in the 20%, and you can stop quickly if it isn't working.
The NICE decision to allow only one of these to be used with any patient was on the basis of cost. However, this dated back to when Abiraterone was very expensive (no longer is due to patent having expired), although NICE haven't ungraded their guidance in the light of it being much cheaper now. Enzalutamide patent expires in the UK in 2028. It expires in the US in 2027, and some generic Enzalutamide medications already have FDA approval to launch from the expiry date in the US.
I would not expect serial use of Enzalutamide, Daralutamide, and Apalutamide to give any benefit as they all work the same way. However, Abiratrone works slightly differently.